Trials / Withdrawn
WithdrawnNCT00605709
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- BPGbio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell carcinoma by Compound 31510 topical cream.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | API 31510 Topical Cream | Topical treatments to lesion twice daily of randomized treatments. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-07-01
- First posted
- 2008-01-31
- Last updated
- 2012-07-25
Source: ClinicalTrials.gov record NCT00605709. Inclusion in this directory is not an endorsement.